[{"id":"7a1267fa-f1d2-4fc1-bf7a-c4921620ad8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565378","created_at":"2022-10-04T15:57:49.680Z","updated_at":"2024-07-02T16:35:18.298Z","phase":"Phase 2","brief_title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT05565378","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1-H","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/14/2022","start_date":" 10/14/2022","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/14/2028","study_completion_date":" 01/14/2028","last_update_posted":"2024-02-21"},{"id":"8596f9da-ccae-4c9a-b6dc-e45f9fa99bab","acronym":"YODO","url":"https://clinicaltrials.gov/study/NCT04052113","created_at":"2021-01-18T19:52:06.969Z","updated_at":"2024-07-02T16:36:33.980Z","phase":"","brief_title":"Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer","source_id_and_acronym":"NCT04052113 - YODO","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1-H"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 03/23/2020","primary_completion_date":" 03/23/2020","study_txt":" Completion: 03/23/2020","study_completion_date":" 03/23/2020","last_update_posted":"2021-03-01"}]